Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.

Reitsma JM, Savaryn JP, Faust K, Sato H, Halligan BD, Terhune SS.

Cell Host Microbe. 2011 Feb 17;9(2):103-14. doi: 10.1016/j.chom.2011.01.006.

2.

Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.

Bigley TM, Reitsma JM, Terhune SS.

J Virol. 2015 Oct;89(20):10230-46. doi: 10.1128/JVI.00986-15. Epub 2015 Jul 29.

3.

Conserved domains and structure prediction of human cytomegalovirus UL27 protein.

Hantz S, Couvreux A, Champier G, Trapes L, Cotin S, Denis F, Bouaziz S, Alain S.

Antivir Ther. 2009;14(5):663-72.

PMID:
19704169
4.

Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.

Webel R, Hakki M, Prichard MN, Rawlinson WD, Marschall M, Chou S.

J Virol. 2014 May;88(9):4776-85. doi: 10.1128/JVI.00192-14. Epub 2014 Feb 12.

5.

Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.

Hakki M, Drummond C, Houser B, Marousek G, Chou S.

Antiviral Res. 2011 Nov;92(2):313-8. doi: 10.1016/j.antiviral.2011.08.019. Epub 2011 Sep 1.

6.

Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.

Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van Den Bogaard M, Stamminger T.

J Gen Virol. 2001 Jun;82(Pt 6):1439-50.

PMID:
11369889
7.

Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.

Herget T, Freitag M, Morbitzer M, Kupfer R, Stamminger T, Marschall M.

Antimicrob Agents Chemother. 2004 Nov;48(11):4154-62.

8.

Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.

Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T.

Antiviral Res. 2000 Oct;48(1):49-60.

PMID:
11080540
9.

Regulatory roles of protein kinases in cytomegalovirus replication.

Marschall M, Feichtinger S, Milbradt J.

Adv Virus Res. 2011;80:69-101. doi: 10.1016/B978-0-12-385987-7.00004-X. Review.

PMID:
21762822
10.

Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.

Reitsma JM, Terhune SS.

Antiviral Res. 2013 Nov;100(2):321-7. doi: 10.1016/j.antiviral.2013.09.011. Epub 2013 Sep 23.

11.

Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.

Chou S.

Antimicrob Agents Chemother. 2009 Jan;53(1):81-5. doi: 10.1128/AAC.01177-08. Epub 2008 Nov 3.

12.
13.

Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.

Chou S, Hakki M, Villano S.

Antiviral Res. 2012 Aug;95(2):88-92. doi: 10.1016/j.antiviral.2012.05.013. Epub 2012 Jun 1.

14.

The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.

Hutterer C, Hamilton S, Steingruber M, Zeitträger I, Bahsi H, Thuma N, Naing Z, Örfi Z, Örfi L, Socher E, Sticht H, Rawlinson W, Chou S, Haupt VJ, Marschall M.

Antiviral Res. 2016 Oct;134:130-143. doi: 10.1016/j.antiviral.2016.08.005. Epub 2016 Aug 8.

PMID:
27515131
15.

Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy.

Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T.

J Gen Virol. 2002 May;83(Pt 5):1013-23.

PMID:
11961255
16.

Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.

Chou S, Ercolani RJ, Marousek G, Bowlin TL.

Antimicrob Agents Chemother. 2013 Jul;57(7):3375-9. doi: 10.1128/AAC.00511-13. Epub 2013 May 6.

17.

Human cytomegalovirus pUL97 regulates the viral major immediate early promoter by phosphorylation-mediated disruption of histone deacetylase 1 binding.

Bigley TM, Reitsma JM, Mirza SP, Terhune SS.

J Virol. 2013 Jul;87(13):7393-408. doi: 10.1128/JVI.02825-12. Epub 2013 Apr 24.

18.

Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.

James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, Prichard MN.

Antimicrob Agents Chemother. 2011 Oct;55(10):4682-91. doi: 10.1128/AAC.00571-11. Epub 2011 Jul 25.

19.

The Interaction between Cyclin B1 and Cytomegalovirus Protein Kinase pUL97 is Determined by an Active Kinase Domain.

Steingruber M, Socher E, Hutterer C, Webel R, Bergbrede T, Lenac T, Sticht H, Marschall M.

Viruses. 2015 Aug 11;7(8):4582-601. doi: 10.3390/v7082834.

20.

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW.

Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.

Supplemental Content

Support Center